P1101 in Treating Patients With Myelofibrosis

Stopped Study drug became commercially available

Conditions

• Primary Myelofibrosis
• Secondary Myelofibrosis

Interventions

• OTHER: Laboratory Biomarker Analysis
• OTHER: Quality-of-Life Assessment
• BIOLOGICAL: Ropeginterferon Alfa-2B

Sponsor

Mayo Clinic